Barclays Capital (NYSE: BCS) upped their price target on shares of Hanger Orthopedic (NYSE: HGR) from $22.00 to $28.00 in a research note issued on Thursday. The firm currently has an “overweight” rating on the stock.
HGR has been the subject of a number of other recent research reports. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Hanger Orthopedic to $27.00 in a research note to investors on Thursday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Hanger Orthopedic in a research note to investors on Friday, February 10th. They now have a $23.00 price target on the stock.
Hanger Orthopedic traded down 2.60% on Thursday, hitting $23.27. Hanger Orthopedic has a 52-week low of $14.57 and a 52-week high of $27.90. The company has a market cap of $790.6 million and a price-to-earnings ratio of 14.51.
The company last announced its quarterly results on Wednesday, May 2nd. It reported $0.22 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.20 EPS by $0.02. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts expect that Hanger Orthopedic will post $0.49 EPS next quarter.
Hanger Orthopedic Group, Inc. owns and operates orthotic and prosthetic (O&P) patient-care centers (patient -care centers) in the United States.